secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001628280-23-022240
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis prices public offering of 11M shares at $22.66, raising ~$235.5M
-------------------------------------------------------------------------

- Sale of 11,032,656 common shares at $22.66 per share; net proceeds estimated at $235.5M.
- Net proceeds to be used for ongoing and planned clinical trials and working capital.
- Closing expected on June 20, 2023, subject to customary conditions.
- Underwriters include Morgan Stanley, Jefferies, and SVB Securities.
- Offering conducted under effective shelf registration statement on Form S-3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000162828023022240/0001628280-23-022240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000162828023022240/zntl-20230615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-022240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer